BNC105P

BNC105P is a benzofuran-based vascular disrupting agent (VDA) prodrug developed for the treatment of solid tumors. It is the disodium phosphate ester prodrug of BNC105, which, upon administration, is rapidly converted to its active form. In activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, leading to disruption of mitotic spindle formation and cell cycle arrest. This results in selective disruption of tumor vasculature, causing hypoxia and apoptosis in tumor cells due to deprivation of nutrients. Additionally, it exerts direct cytotoxic effects on cancer cells by inhibiting tubulin polymerization. Unlike some other agents in this class, BNC105 is not a substrate for the multidrug-resistance P-glycoprotein transporter[1][3][4][6]. The drug has been investigated primarily for malignant mesothelioma and renal cell carcinoma but has also been studied in ovarian cancer and chronic lymphocytic leukemia[7].

Other names

945771-96-0UNII-E3052198GMUNII-E-3052198GMUNII-E 3052198GM